Presented By Christina Tsien at 2014 ASCO Annual Meeting.

Slides:

Advertisements

Similar presentations

Slide 1 Presented By Susan Chang at 2014 ASCO Annual Meeting.

Advertisements

Presented By Anthony Cmelak at 2014 ASCO Annual Meeting

Highlights of the Day II: SARCOMA “The not so Old and the New” Presented By Dennis Priebat at 2014 ASCO Annual Meeting.

Synopsis of FDA Colorectal Cancer Endpoints Workshop Michael J. O’Connell, MD Director, Allegheny Cancer Center Associate Chairman, NSABP Pittsburgh, PA.

Multi trial evaluation of longitudinal tumor measurement (TM)-based metrics for predicting overall survival (OS) using the RECIST 1.1 data warehouse Background:

Lung Cancer: What’s New and What’s Old? Presented By Leora Horn at 2014 ASCO Annual Meeting.

B.M. Ellingson 1,2, M.G. Malkin 1,3,4, S.D. Rand 1,2, J.M. Connelly 3, C. Quinsey 4 P.S. LaViolette 1,5, D.P. Bedekar 1,2, and K.M. Schmainda 1,2,5 B.M.

Presented By Patrick Wen at 2014 ASCO Annual Meeting

Presented By Raymond Huang at 2014 ASCO Annual Meeting

McDaniels – Feb 29, Outline Patient 6 question Patient 11 ADC results Abstract for AAPM conference.

Diffusion MRI is sensitive to brain tumor cell density Clinical ADC and cell density are negatively correlated (Sugahara, 1999; Lyng, 2000; Chenevert,

CALGB/SWOG 80405: Phase III trial of FOLFIRI or FOLFOX with Bevacizumab or Cetuximab for patients w/ KRAS wild type untreated metastatic adenocarcinoma.

Taylor J Greenwood, MD, Adam Wallace, MD, Aseem Sharma, MD, Jack Jennings, MD, PhD.

Imaging of bevacizumab treated brain: traditional and emerging concepts Asim K. Bag Joel K Cure Aparna Singhal David Wever Asim K. Bag Joel K Cure Aparna.

Regulatory Background and Past FDA Approvals in Colorectal Cancer Amna Ibrahim M.D DODP, FDA.

ACRIN Abdominal Committee ACRIN Gynecologic Committee Fall Meeting 2010.

Shutter-Speed Model DCE-MRI for Assessment of Response to Cancer Therapy U01 CA154602; Wei Huang, PhD, Christopher Ryan, MD; Oregon Health & Science University,

Imaging Genomics: Correlation of Invasive Genomic Composition and Patient Survival Using Qualitative and Quantitative MR Imaging Parameters RR Colen 1,

Surrogate Endpoints and Correlative Outcomes Hem/Onc Journal Club January 9, 2009.

QUANTITATIVE MRI OF GLIOBLASTOMA RESPONSE Bruce Rosen, MD, PhD Athinoula A. Martinos Center for Biomedical Imaging, MGH. Future Plans/Upcoming Trials Reproducibility.

Discussion abstracts Alberto Sobrero MD Ospedale San Martino Genoa, Italy.

Evidence Based For invasive breast cancer BCT is Tumor excision, axillary node dissection, whole breast radiation Modified mastectomy is total mastectomy.

Objective Selection of GBM Imaging Features for Clinical Trials Bradley Erickson, Daniel Blezek, Panos Korfiatis, Jian Su, Ross Mitchell Background: We.

Highlights of the Day: LYMPHOMA Presented By Sonali Smith at 2014 ASCO Annual Meeting.

Prediction of Glioblastoma Multiforme Patient Time to Recurrence Using MR Image Features and Gene Expression Nicolasjilwan, M.1·Clifford, R.2·Flanders,

© NlH National Center for Image Guided Therapy, 2012 ASNR 2012 Imaging Genomic mapping of Edema/Cellular Invasion MRI-Phenotypes in Glioblastoma Multiforme.

Disclosures Paid Consultant, MedQIA LLC Paid Consultant, Agios Pharmaceuticals, Inc. Consultant, Genentech Consultant, Siemens Medical Systems B.M. Ellingson,

ASNR 2012 Methodology for Imaging Genomics of Gliomas

Response rate using conventional criteria is a poor surrogate for clinical benefit on progression-free (PFS) and overall survival (OS) in metastatic colorectal.

Cancer Stem Cells: Some statistical issues  What you would like to do: Identify ways to design studies with increased statistical “power” in clinical.

A phase 3, multicenter, randomized, double-blind, placebo-controlled trial of lenvatinib (E7080) in patients with 131I-refractory differentiated thyroid.

Diffusion Physics H 2 O in the body is always in random motion due to thermal agitation B.M. Ellingson, Ph.D., Dept. of Radiological Sciences, David Geffen.

Bevacizumab may Differentially Improve Survival for Patients with the Proliferative and Mesenchymal Molecular Subtype of Ovarian Cancer Presented By Boris.

FDA’s Public Workshop: Innovative Systems for Delivery of Drugs and Biologics: Scientific, Clinical, and Regulatory Challenges Paul Goldfarb, MD, FACS.

Symptom control in patients with recurrent ovarian cancer Measuring the benefit of palliative chemotherapy in women with platinum refractory/ resistant.

Slide 1 Presented By Pierre-Yves Dietrich at 2014 ASCO Annual Meeting.

Scott Kopetz, MD, PhD Department of Gastrointestinal Medical Oncology

Slide 1 Presented By Christian Hinrichs at 2014 ASCO Annual Meeting.

XXV^ Riunione Nazionale MITO Innovation in gynecologic cancer: optimal therapy, quality of life, precision medicine. Naples, June Targeting.

HE-4 TRIAL Prospective phase II trial on the prognostic and predictive value of HE-4 regression during neoadjuvant chemotherapy for advanced ovarian, Fallopian.

Dr. Marco Matos JOURNAL CLUB GCUH 4/07/14.

Presented By Shin Fujita at 2016 ASCO Annual Meeting

Presented By Alan Venook at 2016 ASCO Annual Meeting

Kelci J. Miclaus, PhD Advanced Analytics R&D Manager JMP Life Sciences

Presented By Lorenz Trumper at 2016 ASCO Annual Meeting

CCO Independent Conference Coverage

A cura di Filippo de Marinis

Mammograms and Breast Exams: When to start /stop mammograms

Highlights: Myeloma Oral Session

Presented By Luca Malorni at 2017 ASCO Annual Meeting

A New Path Forward: Immune Checkpoint Inhibitors in Bladder Cancer

Improving Survival in Glioblastoma Multiforme

What’s the Big Deal About Brain Atrophy and Neurodegeneration in RRMS?

Adília Hormigo, Philip H. Gutin, Shahin Rafii Cancer Cell

Assessing Disease Progression in MS Treatment

Are We Closer to Personalized Medicine in MS?

Treating mRCC After Initial Antiangiogenic Therapy:

Presented By Johanna Bendell at 2016 ASCO Annual Meeting

Comments on design and sequence of biomarker studies

Diffusion Magnetic Resonance Imaging in the Head and Neck

Add or Subtract? x =.

Presented By Steven Park at 2016 ASCO Annual Meeting

Established and novel imaging biomarkers for assessing response to therapy in hepatocellular carcinoma Tao Jiang, Andrew X. Zhu, Dushyant V. Sahani

Plasma Levels Correlate with Clinical Benefit

Presented By Andrew Evens at 2016 ASCO Annual Meeting

Biomarkers as Endpoints

Fig. 1. Brain imaging before surgery

A 5-year-old boy with parietal anaplastic ependymoma.

Figure. (A) Photograph of the patient’s scalp shows the large necrotic skin tumor. Figure. (A) Photograph of the patient’s scalp shows the large necrotic.

Presentation transcript:

Presented By Christina Tsien at 2014 ASCO Annual Meeting

Current Limitations in the Response Assessment of Anti-Angiogenic Therapy Presented By Christina Tsien at 2014 ASCO Annual Meeting

Imaging Changes Following Anti-Angiogenic Therapy Presented By Christina Tsien at 2014 ASCO Annual Meeting

Does Reduction in Enhancement Reflect Anti-Tumor Effect? Presented By Christina Tsien at 2014 ASCO Annual Meeting

Recurrent GBM treated with Bevacizumab: CE-Δ T1-weighted Subtraction Maps Aid Prediction of Survival in a Multi-Center Clinical Trial Presented By Christina Tsien at 2014 ASCO Annual Meeting

Improved Response Rates with Anti-Angiogenic Therapies Does Not Correlate to Improved OS Presented By Christina Tsien at 2014 ASCO Annual Meeting

Physiologic MRI: Imaging Tumor Biology May Improve Response Assessment Presented By Christina Tsien at 2014 ASCO Annual Meeting

Slide 8 Presented By Christina Tsien at 2014 ASCO Annual Meeting

Bi-modal fitted ADC Histogram Analysis Predict 6 mth PFS in Recurrent GBM Tx with Bevacizumab Presented By Christina Tsien at 2014 ASCO Annual Meeting

Bevacizumab Decreases Edema Leading to Improved Clinical Benefit Presented By Christina Tsien at 2014 ASCO Annual Meeting

Vessel Architectural Imaging Presented By Christina Tsien at 2014 ASCO Annual Meeting

Summary Presented By Christina Tsien at 2014 ASCO Annual Meeting

Imaging Biomarkers Ready for Prime Time? Presented By Christina Tsien at 2014 ASCO Annual Meeting

Physiologic Imaging Biomarkers must add value beyond known Clinical Predictors of OS Presented By Christina Tsien at 2014 ASCO Annual Meeting

What are the Challenges in Incorporating Imaging Biomarkers in the Clinic Today? Presented By Christina Tsien at 2014 ASCO Annual Meeting

Diffusion MRI Presented By Christina Tsien at 2014 ASCO Annual Meeting

Summary Presented By Christina Tsien at 2014 ASCO Annual Meeting